Experimental lead neuropathy: inorganic lead inhibits proliferation but not differentiation of Schwann cells.
Schwann cells were prepared from the sciatic nerves of newborn rats and cultured in a monolayer. Addition of lead acetate at concentrations between 0.4 and 10.0 micrograms/ml, levels comparable to those occurring in neural tissues and physiological fluids of lead-intoxicated rats, diminished both the baseline rate of proliferation of the Schwann cells and their response to the mitogens, axolemmal fragments, glial growth factor, and the adenosine 3':5'-cyclic monophosphate (cAMP) analogues 8-bromo-cAMP and dibutyryl-cAMP. This demonstrates a direct toxic effect of inorganic lead on Schwann cells. Lead acetate in this concentration range did not, however, inhibit the cAMP analogue-induced appearance of the "myelin marker" lipid galactocerebroside on the surfaces of the cultured Schwann cells.
Sobue
G
G
Pleasure
D
D
D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn / Q000502:physiology; D001369:Axons / Q000187:drug effects; D003994:Bucladesine / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004492:Edetic Acid / Q000494:pharmacology; D005699:Galactosylceramides / Q000378:metabolism; D007854:Lead / Q000494:pharmacology*; D007855:Lead Poisoning / Q000473:pathology*; D008938:Mitosis / Q000187:drug effects; D009468:Neuromuscular Diseases / Q000139:chemically induced / Q000473:pathology*; D009942:Organometallic Compounds; D051381:Rats; D011919:Rats, Inbred Strains; D012583:Schwann Cells / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D013936:Thymidine / Q000378:metabolism
D005699:Galactosylceramides; D009942:Organometallic Compounds; D015124:8-Bromo Cyclic Adenosine Monophosphate; D007854:Lead; D003994:Bucladesine; D004492:Edetic Acid; C008261:lead acetate; D013936:Thymidine